DNMT3A and angioimmunoblastic T-cell lymphoma: In myeloid malignancies, multiple alterations were noted in TET2 (n = 142, including 24/43 or 56% of AITL samples) and DNMT3A (n = 35), while in mantle cell lymphoma, ATM (n = 14, 10%) frequently harbored multiple mutations.